Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC

Abstract

Even radical surgical treatment of early stage non-small cell lung cancer (NSCLC) does not provide 100% chance to be definitely cured. Adjuvant chemotherapy increases the 5-year survival rates by around 5%.

There have been no advances in adjuvant treatment for a long time. ADAURA is a breakthrough trial.

The trial was unblinded early after overwhelming efficacy in the adjuvant treatment of patients with stage IB-IIIA EGFR (epidermal growth factor receptor)-mutated NSCLC. This article describes ground-breaking ADAURA trial.

Keywords

• NSCLC (non-small cell lung cancer)
• stage IB-IIIA
• EGFR mutation
• osimertinib
• adjuvant treatment